Multivariate analysis using patients' characteristics at baseline on the relative risk of major thrombosis, arterial thrombosis, venous thrombosis, myocardial infarction, stroke plus TIA, and peripheral arterial thrombosis among men and women with polycythemia vera; n = 1638
| . | No. patients . | 10.1 to 15.0 × 109/L white blood cells*† . | More than 15.0 × 109/L white blood cells*‡ . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Major thrombosis | 169 | 1.05 (0.69-1.61) | .811 | 1.24 (0.78-1.96) | .370 |
| Arterial thrombosis | 121 | 1.07 (0.65-1.76) | .802 | 1.21 (0.69-2.11) | .508 |
| Venous thrombosis | 51 | 1.02 (0.47-2.21) | .963 | 1.28 (0.56-2.92) | .554 |
| Myocardial infarction | 41 | 0.82 (0.31-2.16) | .683 | 2.27 (1.00-5.15) | .049 |
| Stroke/TIA | 54 | 1.32 (0.64-2.70) | .450 | 0.69 (0.26-1.86) | .464 |
| Peripheral arterial thrombosis | 21 | 1.44 (0.44-4.74) | .549 | 1.12 (0.21-6.02) | .892 |
| . | No. patients . | 10.1 to 15.0 × 109/L white blood cells*† . | More than 15.0 × 109/L white blood cells*‡ . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Major thrombosis | 169 | 1.05 (0.69-1.61) | .811 | 1.24 (0.78-1.96) | .370 |
| Arterial thrombosis | 121 | 1.07 (0.65-1.76) | .802 | 1.21 (0.69-2.11) | .508 |
| Venous thrombosis | 51 | 1.02 (0.47-2.21) | .963 | 1.28 (0.56-2.92) | .554 |
| Myocardial infarction | 41 | 0.82 (0.31-2.16) | .683 | 2.27 (1.00-5.15) | .049 |
| Stroke/TIA | 54 | 1.32 (0.64-2.70) | .450 | 0.69 (0.26-1.86) | .464 |
| Peripheral arterial thrombosis | 21 | 1.44 (0.44-4.74) | .549 | 1.12 (0.21-6.02) | .892 |
Multivariable model adjusted for information colleted at baseline, including white blood cells (3 categories), age (2 categories), sex, time from PV diagnosis to recruitment (2 categories), thrombotic or hemorrhagic events prior to recruitment (yes/no), smoking (yes/no), history of diabetes (yes/no), hypertension (yes/no), intermittent claudication (yes/no), erythromelalgia (yes/no), splenomegaly (yes/no), circulating immature cells (yes/no), hematocrit (tertiles), platelet count (tertiles), total blood cholesterol (2 categories), phlebotomy use (yes/no), interferon use (yes/no), hydroxyurea use (yes/no), antiplatelet use (yes/no), anticoagulant use (yes/no), 32P use (yes/no), busulfan use (yes/no), chlorambucil use (yes/no), and pipobroman use (yes/no).
Reference category: ≤ 10.0 × 109/L (n = 990 [62.0%]).
n = 365 (22.9%).
n = 241 (15.1%).